Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6136794A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 29, 1999 |
| Grant date | Oct 24, 2000 |
| Priority date | — |
| Expiry date | Jan 29, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.